Bozena Cybulska-Stopa
Overview
Explore the profile of Bozena Cybulska-Stopa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hossain S, Gimenez G, Stockwell P, Weeks R, Almomani S, Jones G, et al.
Cancer Lett
. 2025 Mar;
:217638.
PMID: 40089202
Successful immune checkpoint inhibitor (ICI) therapy occurs in only a fraction of melanoma patients, and yet all patients are susceptible to potentially serious ICI-related side-effects. No current biomarkers robustly predict...
2.
Rosciszewska-Zukowska I, Kulakowska A, Kalinowska A, Bartosik-Psujek H, Mirowska-Guzel D, Stasiolek M, et al.
Neurol Neurochir Pol
. 2025 Jan;
59(1):20-32.
PMID: 39811975
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that is usually diagnosed between the ages of 20 and 40. Changes in the immune system...
3.
Placzke J, Rosinska M, Sobczuk P, Zietek M, Kempa-Kaminska N, Cybulska-Stopa B, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686659
Background: The landscape of melanoma management changed as randomized trials have launched adjuvant treatment. Materials And Methods: An analysis of data on 248 consecutive melanoma stage III and IV patients...
4.
Leszek P, Klotzka A, Bartus S, Burchardt P, Czarnecka A, Dlugosz-Danecka M, et al.
Kardiol Pol
. 2023 Sep;
81(10):1047-1063.
PMID: 37660389
No abstract available.
5.
Zietek M, Teterycz P, Wierzbicki J, Jankowski M, Las-Jankowska M, Zegarski W, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345002
Background: In melanoma treatment, an approach following positive sentinel lymph node biopsy (SLNB) has been recently deescalated from completion lymph node dissection (CLND) to active surveillance based on phase III...
6.
Sigorski D, Wilk M, Gawlik-Urban A, Salek-Zan A, Kiszka J, Malik M, et al.
Front Oncol
. 2023 Apr;
13:1108937.
PMID: 37077831
Background: Abiraterone acetate (ABI) and Enzalutamide (ENZA) are second-generation hormone drugs that show breakthrough activity in post-chemotherapy, metastatic castration-resistant prostate cancer (mCRPC). The leading oncological and urological guidelines indicate both...
7.
Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus L, Ziolkowska B, et al.
Melanoma Res
. 2023 Apr;
33(3):208-217.
PMID: 37015054
Pembrolizumab and nivolumab (anty-PD-1 antibody) are commonly used for the treatment of melanoma patients. However, their efficacy and safety have never been directly compared, leaving little guidance for clinicians to...
8.
Piejko K, Cybulska-Stopa B, Zietek M, Dziura R, Galus L, Kempa-Kaminska N, et al.
Target Oncol
. 2023 Mar;
18(2):235-245.
PMID: 36906728
Background: Combined treatment with BRAFi and/or MEK inhibitors (MEKi) improves outcomes in advanced melanoma patients in comparison with monotherapy. Objective: We aim to report real-world treatment efficacy and safety of...
9.
Zietek M, Zdzienicki M, Wierzbicki J, Cybulska-Stopa B, Krotewicz M, Lobaziewicz W, et al.
Postepy Dermatol Alergol
. 2023 Jan;
39(6):1141-1150.
PMID: 36685997
Introduction: Within stage III melanoma prognosis and outcomes significantly vary. Advances in systemic therapy improved prognosis in metastatic melanoma. Adjuvant therapy in stage III significantly lowered relapses, although the effect...
10.
Placzke J, Teterycz P, Quaglino P, Cybulska-Stopa B, Tucci M, Rubatto M, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497248
Stage IV melanoma patients develop melanoma brain metastases (MBM) in 50% of cases. Their prognosis is improving, and its understanding outside the context of clinical trials is relevant. We have...